Posted on 02/16/2021 8:38:27 PM PST by SeekAndFind
The FLCCC Alliance wishes to respond to Merck’s public statements on February 4th, claiming a lack of sufficient evidence for ivermectin’s efficacy in COVID-19.*
Merck’s assessments of ivermectin’s efficacy in COVID-19 are in striking contrast with the findings reported by multiple expert group’s systematic reviews from across the globe, including metaanalyses of the updated scientific literature:
a. The Front-Line Covid-19 Critical Care Alliance[1]
b. UNITAID/W.H.O Expert Consultant, Dr. Andrew Hill[2]
c. The Evidence Based Medicine Consultancy[3]
d. The National Institutes of Health Treatment Guidelines Panel[4]
e. Kalfas et al, University of Melbourne[5]
f. Padhy et al, All India Institute of Medical Sciences[6]
g. Covid-19 Study Group at https://ivmmeta.com/[7]
h. University of Lyon Dept. of Pharmacology: www.metaevidence.org[8]
_____________________________
MERCK STATEMENT 1: “No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies."
FLCCC RESPONSE: The above publications cite in vitro and animal studies demonstrating anti-viral and anti-inflammatory mechanisms of action with ivermectin.[9-14] Further, eight trials in COVID-19 patients reported a dose-dependent significant reduction in both viral load and time to viral clearance. [2]
_____________________________
MERCK STATEMENT 2: "No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease."
FLCCC RESPONSE: The above publications cite ten trials that consistently reported a sizable significant reduction in time to clinical recovery, length of hospitalization, or mortality.[2],[15-18] Further, epidemiologic analyses reported consistent and large population-wide reductions in case-fatality rates and excess deaths in regions with ivermectin distribution campaigns .[19]
_____________________________
Merck STATEMENT 3: "A concerning lack of safety data in the majority of studies."
FLCCC RESPONSE: The above publications cite numerous safety studies over decades of use, reporting an extremely low incidence of severe side effects.[20,21]
Further, many studies and case series demonstrate the safety of both escalating and prolonged dosing of ivermectin in both healthy and ill patients. [22,23]
Unfortunately, Merck’s website did not provide the scientific data or bibliography to support its brief posted statements. The above reviewed in vitro, clinical, and epidemiologic evidence indicates that the current evidence base strongly contradicts Merck's conclusions.
Merck’s stated mission is "to discover, develop and provide innovative products and services that save and improve lives around the world.” Merck's historic impact on the discovery of ivermectin and their subsequent decision to donate hundreds of millions of doses to W.H.O programs led to the eradication of a scourge of parasitic diseases across many parts of the world.[24]
Many experts recognized Merck's partnership with public health care agencies decades ago as one of last century's most significant medical accomplishments. We remind Merck of the words of their founders' son, George W. Merck, who, in 1950, stated, "We try never to forget that medicine is for the people. It is not for profits. The profits follow, and if we have remembered that they have never failed to appear. The better we have remembered it, the larger they have been”.
Our sincere hope is that the mounting evidence in favor of ivermectin's efficacy and safety in COVID-19 will lead Merck to support the design and conduct of ethically appropriate clinical trials to identify the best timing, dose, and duration of ivermectin in the prophylaxis and treatment of COVID-19. Now more than ever, during the worst pandemic of the last 100 years, the world would benefit from Merck's scientists and organization's resources to advance knowledge with the hope of recreating in this century the most significant medical accomplishments of the last century.
Sincerely,
The Front Line Covid-19 Critical Care Alliance
Pierre Kory, MD
Keith Berkowitz, MD
Paul E. Marik, MD
Howard Kornfeld, MD
G. Umberto Meduri, MD
Fred Wagshul, MD
Joseph Varon, MD
Scott Mitchell, MBChB
Jose Iglesias, DO
Eivind Vinjevoll, MD
Eric Osgood, MD
REFERENCES:
* https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/
1. Kory P, Meduri GU, Varon J et al. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Frontiers in Pharmacology. 2021. doi: 10.3389/fphar.2021.643369
2. Hill A, Abdulamir AS, Ahmed A et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Research Square. 2021. 10.21203/rs.3.rs-148845/v1
3. Lawrie T. Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. ResearchGate. 2021. https://b3d2650e-e929-4448-a527- 4eeb59304c7f.filesusr.com/ugd/593c4f_1b1399cb64514dc4bdcbef0cd15f7878.pdf
4. NIH Treatment Guidelines Panel. The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19. 2021.
https://www.covid19treatmentguidelines.nih.gov/statement-onivermectin/
5. Kalfas S, Visvanathan K, Chan K, Drago J. The therapeutic potential of ivermectin for COVID-19: A review of mechanims and evidence. medRxiv. 2020. doi.org/10.1101/2020.11.30.20236570
6. Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential
of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2020;23:462-469.
7. COVID-19 Studies Group. Ivermectin is effective for COVID-19: real-time meta analysis of 37 studies. 2021. https://ivmmeta.com/
8. University Hospital of Lyon -Pharmacology and Toxicology Department CRDatPHC. Meta-evidence COVID-19. 2021. http://www.metaevidence.org/viewMApredictive2.aspx?expositio n=684&comparator=649&pathology=87&domain=12&selFocus=2
9. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
10. Dayer MR. Coronavirus (2019-nCoV) Deactivation via Spike Glycoprotein Shielding by Old Drugs, Bioinformatic Study. 2020.
11. Hussien MA, Abdelaziz AE. Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARSCoV-2 ACE2 receptor and main protease. Network Modeling Analysis in Health Informatics and Bioinformatics. 2020;9(1):1-18.
12. Dasgupta J SU, Bakshi A, Dasgupta A, Manna K, Saha, C De, RK, Mukhopadhyay S, Bhattacharyya NP. Nsp7 and Spike Glycoprotein of SARS-CoV-2 Are Envisaged as Potential Targets of Vitamin D and Ivermectin. Preprints. 2020.
13. Lehrer S, Rheinstein PH. Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In Vivo. 2020;34(5):3023-3026.
14. Swargiary A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies. 2020.
15. Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. 2020.
16. Elgazzar A, Hany B, Youssef SA, Hafez M, Moussa H. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. 2020.
17. Niaee MS, Gheibi N, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. 2020.
18. Spoorthi V SS. Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV2. International Archives of Integrated Medicine. 2020;7(10):177-182.
19. Chamie J. Real-World Evidence: The Case of Peru. Causality between Ivermectin and COVID-19 Infection Fatality Rate. 2020.
20. Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. J Drugs Dermatol. 2016;15(3):325-332.
21. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. The Lancet. 1997;350(9070):18-22.
22. Guzzo C, Furtek C, Porras A, et al. Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects. Journal of clinical pharmacology. 2002;42:1122-1133.
23. de Castro Jr CG, Gregianin LJ, Burger JA. Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID19 infection. Leukemia & Lymphoma. 2020;61(10):2536-2537.
24. Tambo E, Khater EI, Chen JH, Bergquist R, Zhou XN. Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty. (2095-5162 (Print)).
Ping for your interest
This is a statement by the FLCCC that counters Merck’s statements that ivermectin is ineffective for Covid-19. You will have to click on the link to see the FLCCC statement n PDF format. Here I posted it in text format for those who do not have PDF readers on their computer.
So on the one hand, FLCCC is praising Merck for its past work with regard to ivermectin, but here it is rebutting them.
These people cannot be any more obvious with their bull spit reports/studies.
No prescription if you get it at the Farmer’s CO-OP. Or your doctor can write you a script for Stormectol at the drug store.
Ivermectin (Ivermec) is an anthelmintic (anti-parasite) used to treat infections caused by certain parasites. Ivermectin is available under the following different brand names: Stromectol.
I think ivermectin has its place — sort of. HCQ is yesterdays news, not effective at all. As evidenced by the total lack of support for it.
Ivermectin is a partial treatment. Probably pretty good but not robust as a prophylaxis but in the absence of anything else, not a worthless choice.
As I have said on numerous other threads — If you have the disease and want to survive it...without exception once you have a (+) test and symptoms of mild or moderate disease, and not later than 10 days from symptoms, WITHOUT DELAY, get the infusion of Bamlanivimab or Regenron. These are monoclonal antibodies which arrest disease, convey passive immunity and stop progression. I have seen it save many lives. There is a surplus, because unfortunately our outpatient colleagues are not up to date enough to proactively get this done.
And then there is the more politically charged but evidence based vaccine. This is an excellent prophylaxis. “having the disease with the vaccine” but remaining asymptomatic is a distinction without difference as there have been numerous reports suggesting that asymptomatic spread is actually not that big of a thing. If we stop running 35+ cycles with the nucleic acid augmentation testing, then I think we will see a vast reduction in the cases.
We have evidence based way to STOP this pandemic with monoclonal antibody treatment and vaccine. We no longer have to sniff in the dirt for partial treatments that let way to many people deteriorate to critical illness and death.
While I know I will continue to get flamed by the usual suspects, this is the most robust and reasonable medial evidence there is. Anything else is just political posturing.
All the best to you this evening!
Actually, Ivermectin is a macrolide.
So on the one hand, FLCCC is praising Merck for its past work with regard to ivermectin, but here it is rebutting them....
Did Merck previously support proven Ivermectin?
When I had symptoms and went for a test the doctor recommended to get this treatment if positive test. It was negative but it’s interesting to read about it because I had never heard of it before and the doc didn’t go so far as to explain what exactly it is.
I’ve got mine, however I’ve always read of Ivermectin being used in conjunction with Doxycycline.
PREDICTION: I will one day have the most parasite-free horses in the country. :)
Here -— I’ll translate for Merck -— “We can’t make any money on invermectin!”
Yes you read it well: retail price is below what you would tip for your coffee at Starbucks. I am not talking here about the price of your latté, which is immensely more expensive than that of the potentially life-saving ZIVERDO Therapy.
But who developed this therapy? Well, drawing from its composition, it appears that it can be attributed to none other than the esteemed Professor Thomas Borody, from Australia, whom we interviewed last September and who had even the audacity to claim that COVID-19 was “easier than treating the flu.”
Professor Thomas Borody Interview – Part 1
“We Know it’s Curable; It’s Easier than Treating the Flu” — Professor Thomas Borody
The ZIVERDO therapy is made of 3 agents:
Z stands for Zinc
IVER stands for Ivermectin
DO stands for Doxycycline
https://covexit.com/did-you-hear-about-the-ziverdo-therapy-for-covid-19/
Mystery plunge in coronavirus cases in India baffles experts
Do you think it might be due to the following - you posted
India’s Lucknow district administration to set up kiosks for distribution of Ivermectin tablets for Covid-19 patients
Hindustan Times ^ | 02/13/2021 | HT Correspondent | Hindustan Times, Lucknow
Posted on 2/14/2021, 12:35:43 PM by SeekAndFind
You may have seen this already:
https://covexit.com/professor-thomas-borody-interview-part-1/
This is the first part of our interview with the esteemed Professor Thomas Borody, which covers the following aspects:
What is the recommended ivermectin-based tri-therapy
How is this early therapy administered to old and younger people alike
Examples of elderly people “turning the corner” after being treated
The increasing adoption of the tri-therapy in Australia
How has India managed the results they have with neither monoclonal antibodies nor mass vaccination?
I find this quite impressive:
https://freerepublic.com/focus/f-news/3934485/posts?page=40#40
They’ve been using HCQ and Ivermectin for quite some time.
The Merck study concludes that Ivermectin is ineffective for making them a boatload of money.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.